Neoadjuvant

HER2+

ECOG-ACRIN-EA1181
(CompassHER2-pCR):
Phase II Preoperative
THP and Postoperative
HP in Patients Who
Achieve a Pathologic
Complete Response

Part 1 Component of:
The CompassHER2 Trials
COMprehensive use of
Pathologic Response
ASSessment to Optimize
Therapy in HER2-Positive
Breast Cancer

PI: Telli
Sponsor: ECOG-ACRIN

ER+/HER-

If Biomarker Eligible

BRS0124
Umbrella
Randomized
Controlled
Pre-Operative
Trial Testing
Integrative
Subtype Targeted
Therapeutics in
Estrogen Receptor
Positive HER2
Negative Breast
Cancer

PI: Caswell-Jin
Sponsor: Stanford
University